Intravenous tissue-type plasminogen activator for treatment of acute stroke: The standard treatment with alteplase to reverse stroke (STARS) study

JAMA

Volumn 283, Issue 9, 2000, Pages 1145-1150

  Albers, Gregory W ^a,f   Bates, Vernice E ^b   Clark, Wayne M ^g   Bell, Rodney ^c   Verro, Piero ^d   Hamilton, Scott A ^e  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d SETON HALL UNIVERSITY   (United States)

^e Cenentech Inc   (United States)

^f Stanford California and Cofounder   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE CEREBRAL ARTERY; MORTALITY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

EID: 0034161354     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.9.1145     Document Type: Article

References (20)

1. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333:1581-1587.
2. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med. 1999;340:1781-1787.
3. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory: thrombolytic therapy for acute ischemic stroke -summary statement. Neurology. 1996;47:835-839.
4. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation. 1996;94:1167-1174.
5. Albers GW, Easton JD, Sacco RL, Teal P. Anti-thrombotic and thrombolytic therapy for ischemic stroke. Chest. 1998;114(suppl):683S-698S.
6. Zweifier RM, Brody ML, Graves GC, et al. Intravenous tPA for acute ischemic stroke: therapeutic yield of a stroke code system. Neurology. 1998;50:501-503.
7. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke. 1998;29:18-22.
8. Villar-Cordova C, Morgenstern LB, Barnholtz JS, Frankowski RF, Grotta JC. Neurologists' attitudes regarding rtPA for acute ischemic stroke. Neurology. 1998;50:1491-1494.
9. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. Stroke. 1994;25:2220-2226.
10. Van Swieten JC, Koudstaal PJ, Visser MC, et al. Inter-observer agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
11. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset the ATLANTIS Study: a randomized controlled trial. JAMA. 1999;282:2019-2026.
12. The NINDS tPA Stroke Study Group. Intracerebral hemorrhage after intravenous tPA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
13. Katzan IL, Furlan AJ, Way LE, et al. A systematic audit of IV tPA in Cleveland area hospitals [abstract]. Stroke. 1999;30:266.
14. Lopez-Yunez AM, Bruno A, Zurru C, et al. Protocol violations in community-based rtPA use are associated with symptomatic intracerebral hemorrhage [abstract]. Stroke. 1999;30:264.
15. Generalized efficacy of tPA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28:2119-2125.
16. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274:1017-1025.
17. Marler JR, Tilley BC, Lu M, et al. Earlier treatment associated with better outcome in the NINDS tPA Stroke Study [abstract]. Stroke. 1999;30:244.
18. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke. 1998;29:18-22.
19. Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke. 1998;29:1544-1599.
20. Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous tPA: the OSF stroke network experience. Stroke. 2000;31:77-81.